J2KBIO Past Earnings Performance
Past criteria checks 0/6
J2KBIO has been growing earnings at an average annual rate of 16%, while the Biotechs industry saw earnings growing at 16.9% annually. Revenues have been growing at an average rate of 73.4% per year.
Key information
16.0%
Earnings growth rate
-53.3%
EPS growth rate
| Biotechs Industry Growth | 11.7% |
| Revenue growth rate | 73.4% |
| Return on equity | -1.3% |
| Net Margin | -1.1% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
No updates
Revenue & Expenses Breakdown
How J2KBIO makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 30,848 | -331 | 5,213 | 1,402 |
| 31 Dec 23 | 28,472 | 4,844 | 4,332 | 1,217 |
| 30 Sep 23 | 24,780 | 4,100 | 4,000 | 1,118 |
| 30 Jun 23 | 21,088 | 3,390 | 3,797 | 1,076 |
| 31 Mar 23 | 17,791 | 2,501 | 3,559 | 945 |
| 31 Dec 22 | 16,032 | 2,086 | 3,562 | 878 |
| 31 Dec 21 | 14,219 | 1,623 | 3,012 | 778 |
| 31 Dec 20 | 13,858 | 1,475 | 2,599 | 761 |
Quality Earnings: A420570 is currently unprofitable.
Growing Profit Margin: A420570 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A420570 is unprofitable, but has reduced losses over the past 5 years at a rate of 16% per year.
Accelerating Growth: Unable to compare A420570's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A420570 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (41.1%).
Return on Equity
High ROE: A420570 has a negative Return on Equity (-1.34%), as it is currently unprofitable.